Acute pancreatitis [13]

New England Journal of Medicine

Volumn 355, Issue 9, 2006, Pages 961-

  Famularo, Giuseppe ^a   Minisola, Giovanni ^a   De Simone, Claudio ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GABEXATE; PROTEINASE INHIBITOR;

ACUTE PANCREATITIS; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HIGH RISK PATIENT; HUMAN; LETTER; META ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; NOTE; PANCREATITIS;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; COST-BENEFIT ANALYSIS; GABEXATE; HUMANS; INFUSIONS, INTRAVENOUS; PANCREATITIS; PROTEASE INHIBITORS;

EID: 33748175579     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061618     Document Type: Letter

References (6)

1. Whitcomb DC. Acute pancreatitis. N Engl J Med 2006;354:2142-50.
2. Seta T, Noguchi Y, Shimada T, Shikata S, Fukui T. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol 2004;16:1287-93.
3. Pande H, Thuluvath P. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Drugs 2003;63:1799-812.
4. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 1996;335:919-23.
5. Mariani A. Pharmacological prevention of post-ERCP pancreatitis: which therapy is best? JOP 2003;4:68-74.
6. Masci E, Cavallini G, Mariani A, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003;98:2182-6.